You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Its authors said the guidance provides a focus on how clinicians can get the most efficacy and highest quality results from implementing best practices.
The group said the recommendations aim to standardize and improve warfarin response genotyping assays.
The group now states that men with unfavorable intermediate-risk or high-risk disease can consider testing with Myriad's Prolaris or GenomeDx's Decipher.
Amid rapid adoption of multi-gene panels, ACMG experts are seeing some doctors and patients taking actions they shouldn't.
Absent sufficient evidence to support genetic testing for all patients, the group recommended following existing guidelines, which are based on clinical factors.
The guidelines place a stronger emphasis on pancreatic cancer risk genes, and broaden testing recommendations for those with Ashkenazi Jewish ancestry.
The firm is adding data on patient risk for radiographic progression and cardiovascular events to the test, which was recently included in the ACR guidelines.
The new list comprises 122 test categories — 46 general IVDs, 69 IVDs for specific diseases, and seven test categories for screening blood donations.
CPIC wants to issue guidelines for non-actionable genes, standardize PGx terms, and work with groups like ClinGen and ClinVar to expand use of its guidelines.
The guidelines, drafted with support from PerkinElmer, calls for universal screening of pregnant women for preterm preeclampsia during the first trimester.